Contact
searchSearch
HMP Global
Login

March 2016

Feature

Perspectives
Impact of Government Cost Controls on Treatment Selection for Clinical Pathways
03/08/2016
Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...
Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...
...
03/08/2016
Journal of Clinical Pathways
Research Reports
Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices
03/08/2016
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....
...
03/08/2016
Journal of Clinical Pathways

Column

Counterpoint
ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways
03/08/2016
The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...
The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...
The...
03/08/2016
Journal of Clinical Pathways
Viewpoint
Greater Alignment Among Oncology Clinical Pathways is Needed
03/08/2016
A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...
A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...
A...
03/08/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Calling it Quits: Addressing Treatment Discontinuation on a Clinical Pathway
03/08/2016
Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...
Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...
...
03/08/2016
Journal of Clinical Pathways

Insights

Interview
Immunotherapies and the Future of Cancer Care
03/08/2016
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five years ago, at the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2011; Chicago, IL), investigators presented data on the immunotherapy drug ipilimumab, the first treatment to improve...
Five...
03/08/2016
Journal of Clinical Pathways
Interview
The ASCO Perspective on Oncology Clinical Pathways
03/08/2016
In the face of rising health care costs, oncology clinical pathways have been well documented as an effective tool for reducing inefficiency and improving quality in cancer care. A 2014 study reviewing 642 patients...
In the face of rising health care costs, oncology clinical pathways have been well documented as an effective tool for reducing inefficiency and improving quality in cancer care. A 2014 study reviewing 642 patients...
In the...
03/08/2016
Journal of Clinical Pathways

News

Conference Coverage
2016 American Society of Clinical Oncology Quality Care Symposium
03/08/2016
JCP Editors
A number of recent initiatives have required health care providers to think more proactively about the value of the care they deliver. This is especially true in the treatment of patients with cancer, where...
A number of recent initiatives have required health care providers to think more proactively about the value of the care they deliver. This is especially true in the treatment of patients with cancer, where...
...
03/08/2016
Journal of Clinical Pathways

Department

Research in Review
Stereotactic Body Radiation More Cost-Effective for Treating Prostate Cancer Than Standard Therapy
03/08/2016
JCP Editors
Stereotactic body radiotherapy (SBRT) with a robotic system is currently more cost-effective than standard regimens as well as SBRT delivered with other systems for the treatment of prostate cancer, according to a...
Stereotactic body radiotherapy (SBRT) with a robotic system is currently more cost-effective than standard regimens as well as SBRT delivered with other systems for the treatment of prostate cancer, according to a...
...
03/08/2016
Journal of Clinical Pathways
Research in Review
Drug Combinations Cost-Effective for Reducing Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma
03/08/2016
JCP Editors
A study comparing seven prophylaxis strategies for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma receiving chemotherapy found that routine primary prophylaxis (PP) with...
A study comparing seven prophylaxis strategies for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma receiving chemotherapy found that routine primary prophylaxis (PP) with...
...
03/08/2016
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

April 2016 Volume 2

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use